Species of the parasitic protozoan genus Leishmania are the causative agents of a wide variety of human cutaneous, mucocutaneous, and visceral diseases. These organisms reside throughout their digenetic life cycles in hydrolytic environs, ie, as extracellular, flagellated promastigote forms in the alimentary tract of their sandfly vector hosts and as obligate intracellular amastigote forms within the phagolysosomal system of macrophages in their mammalian hosts. In the latter hosts, cutaneous (eg L tropica, L major, and L mexicana) and mucocutaneous (eg, L braziliensis) species reside within, and are generally restricted to, macrophages of the skin and/or the mucous membranes, whereas viscerotropic species (eg, L donovani, L aethiopica, L infantum, and L chagasi) inhabit tissue macrophages of the spleen, liver (ie, Kupffer cells), and bone marrow [l-141.How these organisms transform, survive, and respond to signals within their infected hosts is unknown. However, considering that all physiologic and biochemical interactions between host and parasite occur, at least temporally, at or across such membranes (eg, they are in direct confrontation with both host immune and nonimmune responses, and all of an organism's nutrient requirements, as well as its secretory and metabolic excretory products, must traverse them), they must obviously play a central role in the survival and maintenance of the parasite within the infected host. Therefore, knowledge of the chemical, enzymatic, and antigenic composition of surface membranes are of import in defining the mechanisms by which Leishmania survive. Further, the identification of unique parasite surface membrane constituents may prove useful as adjuncts in the clinical diagnosis of leishmania1 infections in addition to serving as potential targets for the design of new and more effective chemotherapeutic agents and/or immunoprophylactic therapies.